UroGen Pharma (URGN) Noncash Inprocess Research And Development Expense — Quarterly & Annual

Screener

Noncash Inprocess Research And Development Expense at other companies

RFL

Rafael Holdings, Inc.RFL

$31.58M0.0%

CTO

Citius Oncology, Inc.CTOR

$71.11M-3.1%

Erasca, Inc.ERAS

$150M—

Erasca, Inc.ERAS

$150M—

GlaukosGKOS

$1.5M—

Aclaris TherapeuticsACRS

$21.73M+1,211%

Other financials

Income statement

Revenue$72.5M+199%

Net income-$14.4M+71.3%

Balance sheet

Cash & equivalents$79.1M-14.8%

Total debt$197.5M+55.0%

Total equity-$132.4M-41.8%

Total assets$252.6M+21.0%

Cash flow

Operating cash flow-$33.0M+17.1%

CapEx$60.0K-57.4%

Free cash flow-$33.1M+17.3%

Valuation

Market cap$2.26B+145%

Enterprise value$2.38B+148%

P/S12×+2.2×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-51.7%-21.0pp

FCF margin-84.3%-22.2pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio3.8×-0.3×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept urgn:NoncashInprocessResearchAndDevelopmentExpense.

The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026. Open the filing →

Filed: Aug 5, 2026, 8:05 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001437749-26-025794

FAQ

What is UroGen Pharma's noncash inprocess research and development expense?: UroGen Pharma (URGN) reported noncash inprocess research and development expense of $0 in Q2 2026.
What does noncash inprocess research and development expense mean?: Noncash Inprocess Research And Development Expense as reported by UroGen Pharma Ltd. Ordinary Shares.

Ask your AI about UroGen Pharma's noncash inprocess research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk